Adicet Bio, Inc. — 10-Q Summary
Important issuer discrepancy: The supplied filing is for resTORbio, Inc. (Nasdaq: TORC), not Adicet Bio, Inc. It reports the quarter ended September 30, 2019 and was signed November 5, 2019. This summary reflects the filing text provided; verify that it is the intended document.
Business context and reporting period
resTORbio was a clinical-stage biopharmaceutical company developing RTB101, a TORC1 inhibitor, for aging-related conditions. It had no product revenue and devoted substantially all resources to research and development. The filing covers the three and nine months ended September 30, 2019, compared with the corresponding 2018 periods.
Key financial metrics
| Metric | Q3 2019 | Q3 2018 | Nine months 2019 | Nine months 2018 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $22.1M | $6.8M | $47.5M | $26.7M |
| General and administrative expense | $3.0M | $2.3M | $8.5M | $6.6M |
| Net loss | $24.4M | $8.4M | $53.8M | $31.9M |
| Net loss per share, basic and diluted | $0.68 | $0.30 | $1.51 | $1.23 |
| Operating cash used | Not stated for quarter | Not stated for quarter | $48.0M | $27.8M |
At September 30, 2019, cash and cash equivalents were $23.6M and marketable securities were $93.6M, totaling $117.3M. Total assets were $122.0M, total liabilities $12.2M, and stockholders’ equity $109.8M. The filing reports no credit facility or committed capital source and no debt balance is identified. Profitability and margins are not meaningful because the company had no product revenue and sustained operating losses.
Material changes versus the prior comparable period
- Quarterly research and development expense rose by $15.4M year over year, primarily reflecting clinical-trial costs, including the Phase 3 program. Nine-month R&D expense increased by $20.8M.
- Quarterly net loss increased by $16.0M; the nine-month net loss increased by $22.0M.
- Operating cash use increased by $20.2M for the nine-month period. Financing provided $56.5M, including $49.7M net proceeds from a 2019 public offering and $6.7M from at-the-market sales. Cash and cash equivalents increased $16.6M during the period.
- Common shares outstanding increased from 28.1M at December 31, 2018 to 36.4M at September 30, 2019, mainly through offerings.
Outlook, risks, contingencies, and unusual items
- Management said available cash, cash equivalents, and marketable securities were expected to fund the current operating plan through 2020, including the pivotal PROTECTOR Phase 3 program; the filing cautions that assumptions could prove incorrect and additional financing may be needed.
- PROTECTOR 1 had completed enrollment of 1,024 patients; top-line results were expected by early Q1 2020. PROTECTOR 2 was planned to begin in the Northern Hemisphere in Q4 2019, with about 1,600 patients and results expected in mid-2020.
- A Phase 1b/2a Parkinson’s disease trial of RTB101 alone or with sirolimus began in April 2019; data were expected in 2020. These are forward-looking expectations, not reported outcomes.
- In May 2019, Phase 3 initiation triggered a $2.5M Novartis license milestone, recorded in R&D expense. The license also includes potential future clinical, regulatory, and commercial milestones and tiered royalties; remaining milestones and royalties were not considered probable at quarter-end.
- The company amended its Boston office lease for a seven-year term beginning August 1, 2019; disclosed future minimum payments totaled $4.3M. A $0.2M cash-collateralized letter of credit was issued.
- The filing reports no material litigation, no material changes to previously disclosed risk factors, and effective disclosure controls. Key risks include clinical and regulatory failure or delays, continued losses, uncertain future financing, reliance on third-party research and manufacturing providers, and possible shareholder dilution.
Most important facts for investors to verify
- Confirm the intended issuer: the provided filing is resTORbio, Inc. (TORC), not Adicet Bio, Inc.
- Check subsequent filings for actual PROTECTOR trial timelines and results, and changes to development plans.
- Review cash burn, financing activity, and the assumptions behind the stated runway through 2020.
- Verify the impact of the Novartis license, including the triggered milestone and potential future obligations.
- Assess dilution from equity offerings and equity awards, and the financial effect of the amended lease.